Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report.
Exp Ther Med
; 23(6): 409, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-35619629
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Exp Ther Med
Year:
2022
Document type:
Article
Affiliation country:
Japón
Country of publication:
Grecia